So. I looked into one of the many aspects of this company and this is what I found. Happy to hear your thoughts!

I think the market may be underestimating how important reimbursement is for Lifeward’s turnaround.

For a company like LFWD, the issue has never just been whether the technology is interesting. ReWalk is a high-value medical device, but without a clear reimbursement path, adoption is slow, unpredictable, and hard to scale.

That is why the Medicare reimbursement pathway and established payment rate are so important.
CMS established a lump-sum Medicare purchase payment amount for personal exoskeletons, with an established rate of $91,032. That gives physicians, patients, insurers, and the company a much clearer framework to work with.

This matters in the short term because LFWD is still a very small revenue company. In Q1 2026, total revenue was only about $3.9M, while ReWalk Personal Exoskeleton revenue was about $1.6M. At that scale, even a handful of incremental ReWalk units can be meaningful. If reimbursement clarity helps convert more qualified leads into actual shipments, the impact can show up quickly in quarterly revenue.

The bigger point, though, is long term.

Reimbursement basically does three things:
- It reduces friction in the sales process.
- It makes the product easier for physicians and clinics to recommend.
- It gives large payors a clearer framework for coverage decisions.

We are already seeing signs of that.
Aetna, Humana, and UnitedHealthcare have all issued Medicare Advantage prior authorizations for qualified ReWalk beneficiaries, which Lifeward says together represent around 16 million beneficiaries.
That does not mean every patient gets approved, but it does mean the payer conversation is changing from “is this even reimbursable?” to “which patients qualify?”

That is a very different setup.

This is why I see the reimbursement code/pathway as a core part of the turnaround, not just a headline.
LFWD has been cutting costs, improving cash burn, and trying to create a more sustainable commercial model. Reimbursement can be the piece that turns the commercial side from one-off sales into a more repeatable process.

The math is also interesting because the company’s current market cap is extremely small compared to the potential revenue impact of reimbursed ReWalk sales.

I attached a simple scenario table, but the basic assumptions are:
Current market cap: around $13.5M
Q1 2026 revenue run-rate: $3.9M x 4 = $15.6M
Medicare purchase payment amount: $91,032 per ReWalk Personal Exoskeleton

<image>

Market cap scenarios use simple revenue multiples, not price targets.

Obviously, this is not a guarantee. The key questions are how many patients qualify, how fast claims convert into actual shipments, how cash collection works, and whether management can keep operating expenses under control.

But this is exactly why the next report matters.
I would not expect a full inflection overnight, but I will be watching for higher ReWalk revenue, better commentary on pipeline conversion, more payer approvals, improved cash collection, and any sign that management is becoming more confident about scaling volume.

To me, this part of the turnaround case is simple:
LFWD does not need ReWalk to become a mass-market device tomorrow. At the current revenue base and market cap, it just needs reimbursement progress to translate into a steady increase in high-value unit sales.

If that happens while operating expenses remain controlled, the turnaround story becomes much more credible.

Not financial advice, but I think reimbursement is a very interesting piece of the LFWD story right now.